ROS-responsive PEGylated ferrocene polymer nanoparticles with improved stability for tumor-selective chemotherapy and imaging.
Cancer therapy
Ferrocene polymer
Imaging
Nanotherapeutic
PEGylation
ROS-responsive
Journal
Materials today. Bio
ISSN: 2590-0064
Titre abrégé: Mater Today Bio
Pays: England
ID NLM: 101757228
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
21
05
2023
revised:
27
07
2023
accepted:
15
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Ferrocene-based nanoparticles have garnered interest as reactive oxygen species (ROS)-responsive nanocarriers of anticancer drugs and imaging agents. However, their biomedical applications remain limited due to their poor physiological stability. PEGylation of nanocarriers improves their stability and biocompatibility. In this study, we aimed to develop novel PEG-ferrocene nanoparticles (PFNPs) with enhanced stability and ROS responsiveness for the delivery of paclitaxel (PTX) and imaging agents. PEGylation improved the stability of ferrocene nanoparticles, inhibiting their ROS-responsive destruction. Several PEG-ferrocene polymers containing different molar ratios of methacrylic acid and poly (ethylene glycol) methyl ether methacrylate was designed for optimization. ROS-responsive polymers with optimal monomer ratios were self-assembled into PFNPs with enhanced stability. The PFNPs distended, effectively releasing encapsulated PTX and imaging agents within 8 h in the presence of ROS. Furthermore, they remained stable, with no changes in their hydrodynamic diameters or polydispersity indexes after storage in an aqueous solution and biological buffer. The accumulation of PFNPs in a tumor model
Identifiants
pubmed: 37664795
doi: 10.1016/j.mtbio.2023.100774
pii: S2590-0064(23)00234-X
pmc: PMC10468360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100774Informations de copyright
© 2023 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nano Lett. 2014 Nov 12;14(11):6449-55
pubmed: 25333768
Small. 2022 Jun;18(22):e2200299
pubmed: 35521948
ACS Appl Mater Interfaces. 2015 May 20;7(19):10374-85
pubmed: 25909493
Int J Nanomedicine. 2018 May 18;13:2921-2942
pubmed: 29849457
ACS Nano. 2012 Oct 23;6(10):9042-9
pubmed: 23020219
Adv Sci (Weinh). 2020 Jan 31;7(6):1903243
pubmed: 32195104
Acta Biomater. 2021 Apr 15;125:242-252
pubmed: 33657454
Biomacromolecules. 2019 Jul 8;20(7):2441-2463
pubmed: 31117357
Biomater Sci. 2023 Feb 14;11(4):1182-1214
pubmed: 36606593
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Mar;13(2):e1670
pubmed: 32949116
Pharm Res. 2012 Dec;29(12):3273-7
pubmed: 22806405
Int J Nanomedicine. 2020 Apr 21;15:2659-2668
pubmed: 32368047
J Mater Chem B. 2019 Feb 14;7(6):1005-1016
pubmed: 32255105
Adv Healthc Mater. 2021 Mar;10(5):e2000834
pubmed: 33073497
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Carbohydr Polym. 2014 Dec 19;114:27-35
pubmed: 25263860
Bioeng Transl Med. 2016 Jul 05;1(3):239-251
pubmed: 29313015
Small. 2018 Sep;14(36):e1801571
pubmed: 30079605
Biomaterials. 2011 Oct;32(28):6791-803
pubmed: 21724247
Int J Mol Sci. 2021 Oct 06;22(19):
pubmed: 34639139
Adv Sci (Weinh). 2019 Jan 18;6(5):1801986
pubmed: 30886808
Semin Cancer Biol. 2023 Feb;89:61-75
pubmed: 36682438
Adv Drug Deliv Rev. 2022 Apr;183:114177
pubmed: 35245568
Int J Pharm. 2020 Jun 15;583:119340
pubmed: 32305363
Cancers (Basel). 2022 Jun 10;14(12):
pubmed: 35740534
Expert Opin Drug Deliv. 2021 Feb;18(2):205-227
pubmed: 32969740
J Mater Chem B. 2020 Mar 4;8(9):1906-1913
pubmed: 32043093
Theranostics. 2021 Apr 19;11(13):6370-6392
pubmed: 33995663
Molecules. 2020 Aug 15;25(16):
pubmed: 32824172
Adv Sci (Weinh). 2021 May 16;8(14):2100540
pubmed: 34306980
Biomaterials. 2018 Nov;182:104-113
pubmed: 30114562
J Control Release. 2022 Jan;341:95-117
pubmed: 34774891
Chem Commun (Camb). 2019 Nov 14;55(92):13896-13899
pubmed: 31675022
Cancers (Basel). 2021 Feb 07;13(4):
pubmed: 33562376